Table 5B.
Model-adjusted means* (SEM) and corresponding P-values for health-related outcomes and ADG from Day 0 to Day 60 by treatment group for steers with a WS ≥ 2.
| Parameter | Salinea | FTSa | TILa | TIL + FTSa | P-value FTSα | P-value TILβ | P-value TIL + FTSδ |
|---|---|---|---|---|---|---|---|
| Incoming body weight (lbs) | 649.5 (5.8) | 654.4 (4.2) | 653.5 (4.2) | 660.0 (4.2) | 0.21 | 0.30 | 0.86 |
| BRD retreatment (%) | 15.9 (3.0) | 18.0 (2.2) | 10.2 (1.7) | 10.0 (1.7) | 0.74 | <0.01 | 0.66 |
| Day on Feed (DOF) at BRD retreatment (%) | 20.5 (3.5) | 20.4 (3.0) | 25.1 (3.2) | 31.3 (3.1) | 0.28 | <0.01 | 0.25 |
| BRD 3rd treatment (%) | 6.6 (2.0) | 9.8 (1.7) | 3.7 (1.0) | 3.9 (1.1) | 0.39 | <0.01 | 0.48 |
| BRD case-fatality (%) | Model did not converge | ||||||
| Removals (%) | 4.0 (1.5) | 5.8 (1.3) | 1.8 (0.7) | 1.8 (0.7) | 0.63 | <0.01 | 0.60 |
| DNF (%)b | 5.2 (1.7) | 6.1 (1.3) | 2.3 (0.8) | 1.8 (0.7) | 0.86 | <0.01 | 0.50 |
| ADG (lbs/day)c | 3.2 (0.1) | 3.0 (0.1) | 3.5 (0.1) | 3.6 (0.1) | 0.58 | <0.01 | 0.10 |
Mixed models with a random effect to account for lack of independence among treatment groups within pens, and pens within 2 different sites.
Saline, negative control; FTS, Flunixin transdermal solution; TIL, tildipirosin; and TIL + FTS, concurrent administration of TIL and FTS.
DNF, did not finish; a combination of both calves that died or were removed due to BRD from Day 0 to 60 of this study.
ADG, Average Daily Gain.
P-values reflect the overall effect of FTS, TIL, and their interaction, respectively. P-values for each main effect reflect a model-adjusted average between treatments incorporating the product compared to those that do not. For example, the P-value for the FTS main effect reflects the comparison between treatments that implement FTS (i.e., FTS and TIL + FTS) vs. those that do not (i.e., Saline + TIL). Only when the P-value for the interaction is significant (P ≤ 0.05) are direct comparison made between the four treatment groups.
Model did not converge: Lack of enough observations from Day 0 to 60 to generate a model-adjusted estimate.
P-value for main effect of Flunixin transdermal solution.
P-value for main effect of tildipirosin.
P-value for interaction of tildipirosin and Flunixin transdermal solution.